Gaia Griguolo· @GaiaGriguolo · X·· 2 days agoScore70
Body
PANKU-Breast01 presented at #ESMO26
Iza-bren vs CT in HR+/HER2- after ET and 1 or 2 lines of CT
✅️ significantly improved PFS
Mostly hematologic toxicity, 1% ILD events
@OncoAlert
214 views · 5 likes · 5 reposts · 0 replies
Conference abstracts
LBA50matched by Proffered paper 1: Breast cancer, early and advanced stage
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.orgSource: Gaia Griguolo · x.com